Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.38 |
| ▸ | TUBB | P07437 | 2/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050347 | 1.00 | KDM4E (0.40) | KDM4ETDP1IDO1PYCR1TUBB4A | |
| SCHEMBL4180414 | 0.83 | IDO1 (0.42) | KDM4ETDP1IDO1ALOX15L3MBTL1 | |
| SCHEMBL2874102 | 0.82 | KDM4E (0.39) | KDM4ETDP1IDO1PYCR1TUBB4A | |
| SCHEMBL31096212 | 0.79 | TSHR (0.45) | KDM4ETDP1ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL21823446 | 0.79 | TSHR (0.45) | KDM4ETDP1ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL6867559 | 0.79 | HRH4 (0.38) | TDP1POLBL3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL7828379 | 0.77 | CCR2 (0.33) | TDP1L3MBTL1TSHR | |
| SCHEMBL2653805 | 0.77 | HRH4 (0.38) | TDP1L3MBTL1TSHR | |
| SCHEMBL9914231 | 0.77 | ACHE (0.58) | TDP1ALOX15ATMPOLBL3MBTL1 | |
| SCHEMBL3511278 | 0.77 | CA12 (0.58) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-5470854-A | Antiestrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | KDM4E 406/4885TDP1 185/4885IDO1 683/4885 |
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885TDP1 4559/4885IDO1 3161/4885 |
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | KDM4E 3866/4885TDP1 2422/4885IDO1 2889/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | KDM4E 3866/4885TDP1 2422/4885IDO1 2889/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | KDM4E 406/4885TDP1 174/4885IDO1 1135/4885 |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | KDM4E 3866/4885TDP1 2422/4885IDO1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.